<DOC>
	<DOC>NCT00461500</DOC>
	<brief_summary>This study will compare during 12 weeks, two treatment strategies for Initial Maintenance Therapy : fluticasone propionate alone or the salmeterol/fluticasone propionate combination in adults with moderate persistent asthma</brief_summary>
	<brief_title>SERETIDE 100/50 bd (Twice Daily) Versus FLIXOTIDE 100 bd As Initial Maintenance Therapy In Moderate Asthma In Adults</brief_title>
	<detailed_description>A multicentre randomised, double-blind, parallel-group study to compare the salmeterol/fluticasone propionate combination (SERETIDETM DISKUSTM 50/100) 50/100µg one inhalation twice daily with fluticasone propionate (FLIXOTIDETM DISKUSTM 100) 100µg one inhalation twice daily as initial maintenance therapy for 12 weeks in adults with persistent moderate asthma</detailed_description>
	<mesh_term>Asthma</mesh_term>
	<mesh_term>Fluticasone</mesh_term>
	<mesh_term>Fluticasone Propionate, Salmeterol Xinafoate Drug Combination</mesh_term>
	<mesh_term>Salmeterol Xinafoate</mesh_term>
	<criteria>Inclusion criteria: male or female ≥ 18 documented history of asthma reversibility FEV1 or PEF ≥ 12% (post 400µg salbu) moderate asthma (daily symptoms, daily rescue use, PEF = 6080% predicted value) naive or ≥ 4weeksfree ICS (inhaled corticosteroids) Exclusion criteria: respiratory disorder FEV1&lt;60% predicted exacerbation/respiratory infection ≤ 4 weeks oral/parenteral/depot corticosteroids ≤ 6 months LABA/oral β2 agonist/ ALT/ theophylline ≤ 4 weeks smoker or former smoker ≥ 5 packs year</criteria>
	<gender>All</gender>
	<minimum_age>18 Years</minimum_age>
	<maximum_age>40 Years</maximum_age>
	<verification_date>January 2017</verification_date>
	<keyword>persistent</keyword>
	<keyword>moderate</keyword>
	<keyword>asthma</keyword>
	<keyword>adults</keyword>
	<keyword>Initial</keyword>
	<keyword>Maintenance</keyword>
	<keyword>Therapy</keyword>
</DOC>